Polycythemia vera (PV) is a hematopoietic stem cell neoplasm defined by activating somatic
mutations in the JAK2 gene and characterized clinically by overproduction of red blood cells …

Clonal hematopoiesis (CH) arises when a substantial proportion of mature blood cells is
derived from a single hematopoietic stem cell lineage. Using whole-genome sequencing of …

The goal of therapy for patients with essential thrombocythemia (ET) and polycythemia vera
(PV) is to reduce thrombotic events by normalizing blood counts. Hydroxyurea (HU) and …

In the bone marrow of vertebrates, two types of stem cells coexist—hematopoietic stem cells
(HSCs) and mesenchymal stem cells (MSCs). Hematopoiesis only occurs when these two …

Ischemic stroke has a high recurrence rate despite treatment. This underlines the
significance of investigating new possible cerebrovascular risk factors, such as the acquired …

Arterial (AT) and venous (VT) thrombotic events are the most common complications in
patients with polycythemia vera (PV) and are the leading causes of morbidity and mortality …

Myeloproliferative neoplasms (MPNs) transform to myelofibrosis (MF) and highly lethal acute
myeloid leukemia (AML), although the actionable mechanisms driving progression remain …

Patients with Philadelphia-negative myeloproliferative neoplasms are at high risk of
thrombotic events (TEs). Predisposing factors have been identified in essential …

Widespread adoption of next-generation techniques such as RNA-sequencing (RNA-seq)
has enabled research examining the transcriptome of anucleate blood platelets in health …

The Philadelphia-negative myeloproliferative neoplasms (MPNs) are malignancies of the
hematopoietic stem cell (HSC) arising as a consequence of clonal proliferation driven by …